Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Lyon – page 53

1 185 clinical trials in Lyon, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lyon at a glance
1 185
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

1 185 trials in Lyon

Open in trial search

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Endometrial cancer+3

Not yet recruiting

Study of Disitamab Vedotin for Adults with Previously Treated HER2-Positive Solid Tumors, Including Lung, Head and Neck, Ovarian, and Endometrial Cancers

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Neoplasm

Not yet recruiting

Study on Dostarlimab to Prevent Second Cancer in Patients Cured from Primary Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Centre Leon Berard

Macular oedema

Not yet recruiting

Study on the Effects of RO7200220 for Patients with Uveitic Macular Edema

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg2 Monoclonal Antibody Against Interleukin-6
  • Sponsor:F. Hoffmann-La Roche AG

HIV infection

Not yet recruiting

Study on Switching to Doravirine and Islatravir for People with HIV-1 on Antiretroviral Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cobicistat
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Not yet recruiting

Study on Doravirine and Islatravir for People with HIV-1 Previously Treated with the Same Drug Combination

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Doravirine
  • Sponsor:Merck Sharp & Dohme LLC

Study on Early Detection of Triple-Negative Breast Cancer Relapse Using [68Ga]Ga-FAPI-46 for Patients at High Risk

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Institut Curie

Renal cell carcinoma

Not yet recruiting

Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Exelixis Inc.

Biliary tract disorder

Not yet recruiting

Study on Durvalumab with Chemotherapy for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Lyon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for endometrial carcinoma, bladder cancer, and various solid tumors. Current research explores combination therapies with novel immunotherapy approaches.

  • Triple-negative breast cancer treatments
  • Gastric and esophageal cancer therapies
  • Advanced pancreatic adenocarcinoma

Multiple studies are evaluating targeted therapies and immunological approaches for various tumor types.

02 Immunology and Infectious Diseases

Groundbreaking research in immune system modulation and infectious disease prevention, including studies on COVID-19 vaccines and immune response in critical conditions.

  • Novel COVID-19 intranasal vaccine development
  • Yellow fever vaccine studies
  • ICU-acquired immunosuppression treatment

Focus on developing innovative vaccination strategies and immune system interventions.

03 Chronic Conditions

Studies addressing long-term health conditions, with particular emphasis on kidney disease, cardiovascular health, and metabolic disorders.

  • Chronic kidney disease management
  • Heart failure prevention
  • Hypertriglyceridemia treatment

Innovative approaches combining established and experimental treatments for improved patient outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.